Shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) gapped up prior to trading on Wednesday . The stock had previously closed at $0.21, but opened at $0.22. Actinium Pharmaceuticals shares last traded at $0.25, with a volume of 2,170,475 shares.
Several brokerages have weighed in on ATNM. William Blair began coverage on Actinium Pharmaceuticals in a research report on Thursday, August 8th. They issued an “outperform” rating on the stock. Maxim Group set a $3.00 target price on Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 4th. Finally, Zacks Investment Research lowered Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 4th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Actinium Pharmaceuticals presently has an average rating of “Buy” and an average target price of $3.56.
An institutional investor recently raised its position in Actinium Pharmaceuticals stock. Oppenheimer & Co. Inc. increased its stake in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 69.3% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 175,512 shares of the biotechnology company’s stock after acquiring an additional 71,840 shares during the period. Oppenheimer & Co. Inc. owned 0.15% of Actinium Pharmaceuticals worth $84,000 as of its most recent filing with the SEC.
Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.
Featured Article: What are the benefits of a portfolio tracker?
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.